Details of patient deaths during study period.

Figshare2017-03-22 更新2026-04-29 收录

临床试验安全性

患者结局分析

数据链接：

https://figshare.com/articles/dataset/Details_of_patient_deaths_during_study_period_/4773958 数据链接链接失效反馈

官方服务：

资源简介：

Details of patient deaths during study period.

创建时间：

2017-03-22

Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)

前列腺癌治疗

临床试验安全性

Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)

Figshare2020-12-26 更新70

Gastrointestinal adverse events.

临床试验安全性

胃肠道不良反应监测

aAt least one episode of vomiting PIP dose within an hour of treatment on day 0, day 1, and day 2.bAt least one episode of vomiting on any days between day 0–day 3.cAt least one episode of diarrhea on

Figshare2015-12-02 更新50

Reactogenicity after rAd5 boost by study group.

疫苗反应原性

临床试验安全性

Reactogenicity after rAd5 boost by study group.

NIAID Data Ecosystem50

Summary of Number of participants experiencing grade 3–4 AEs, SAEs or death by treatment and baseline CLcr (mL/min) groups through 96 weeks.

临床试验安全性

肾功能分层

Summary of Number of participants experiencing grade 3–4 AEs, SAEs or death by treatment and baseline CLcr (mL/min) groups through 96 weeks.

NIAID Data Ecosystem60

Cross-tabulation of infection versus indication status for both analysis sets and study conditions.